Reanalysis of the immunological characteristics of scalp psoriasis: a cross-sectional study using Olink proteomics

• by Liping Zhu, Wei Chen, Ningning Shen, Qiang Dong

• July 1, 2026

The therapeutic potential of natural products for pediatric psoriasis: targeting the immune microenvironment

• by Zitong Wang, Jingyu Zhang, Suwen Liu, Hongxiang Chen

• June 24, 2026

FDA Expands Guselkumab Label in PsA

Phase 3b APEX findings support the addition of structural joint damage inhibition data to the prescribing information.

• by Kathryn Wighton

• May 29, 2026

• 2 min

GLP-1 Agents May Reduce Psoriasis Severity

National Psoriasis Foundation review highlights limited evidence and potential metabolic links.

• by Andrea Surnit

• May 5, 2026

• 4 min